ArticleCureus2026
Unmasking Ketosis-Prone Diabetes in a Young Adult.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketosis-prone diabetes (KPD) is a unique clinical entity that does not fit the classic phenotypes of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), although it can present similarly with severe hyperglycemia or diabetic ketoacidosis (DKA). This report describes a patient initially diagnosed with type 2 diabetes mellitus who was subsequently suspected to have ketosis-prone diabetes based on his clinical course. A 22-year-old man presented to the emergency department (ED) with hyperglycemia and was diagnosed with new-onset type 2 diabetes. He was closely monitored by his primary care physician (PCP) and outpatient pharmacist but continued to experience hyperglycemia. He was prescribed increasing doses of insulin, reaching up to 56 units of basal insulin nightly and 12 units of prandial insulin. Antibody testing was mildly elevated, although determined to be clinically insignificant. The patient utilized continuous glucose monitoring (CGM), and after several months of insulin therapy, he experienced hypoglycemic episodes. Consequently, he was titrated off all insulin therapy and successfully maintained euglycemia for eight months before experiencing disease relapse. Ketosis-prone diabetes is challenging to diagnose and remains under-recognized. The Aβ classification system differentiates patients based on the presence or absence of autoantibodies and the presence or absence of β-cell functional reserve. We suspect this patient's presentation is most consistent with the A-β+ phenotype. As indicated by this case, the most challenging management often occurs in the subacute period when β-cell function is unknown. This case underscores the importance of recognizing ketosis-prone diabetes as a distinct clinical entity and highlights the value of close, multidisciplinary team follow-up for chronic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.